# Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

> **NCT03564470** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 120 (estimated)

## Conditions studied

- Leukemia
- Leukemia, Acute
- Leukemia, Lymphoblastic
- Leukemia, B-cell

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT03564470
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-02-14
- **Primary completion:** 2023-08-30
- **Final completion:** 2023-08-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03564470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03564470, "Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL". Retrieved via AI Analytics 2026-09-13 from https://api.ai-analytics.org/clinical/NCT03564470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*